TFF Pharmaceuticals could receive $210M for part in coronavirus treatment development

TFF Pharmaceuticals Inc. is entering the fight against Covid-19, and it could reap big financial rewards for the Austin startup. The clinical-stage biopharmaceutical company announced Aug. 13 a worldwide licensing agreement with Union Therapeutics to use a patented TFF process called thin film freezing that can turn drugs into a dry powder used in an inhaler. Denmark-based Union wants to use thin film freezing to make its drug niclosamide, which is already approved by the United States Food and…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news